GlassScriptPhysician profile
Veronica N Dugan
NPI 1245292515
$16,730.85
in general payments reported to CMS, 2019-2025
48 companies · $2,543 in 2025
The $2,543 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,258 · 2020: $1,933 · 2021: $2,349 · 2022: $2,354 · 2023: $2,516 · 2024: $2,778 · 2025: $2,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,820 · Education: $16.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,819.77 |
| Education | $16.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,919.49 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,789.66 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,494.58 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $1,452.17 | 2019-2025 | |
| Janssen Biotech, INC. | $1,410.92 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $841.62 | 2021-2024 | Zeposia |
| Pfizer INC. | $761.28 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $401.06 | 2019-2024 | Dificid |
| Qol Medical, LLC | $385.46 | 2019-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $283.54 | 2019-2025 | Injectafer |
| Intercept Pharmaceuticals, INC. | $260.18 | 2019-2025 | |
| Lilly USA, LLC | $214.72 | 2023-2025 | Omvoh |
| Boston Scientific Corporation | $212.33 | 2020-2024 | Captivator II, Compliance Endokit |
| Celltrion USA INC. | $210.32 | 2023-2025 | Vegzelma, Yuflyma |
| Genzyme Corporation | $196.00 | 2023-2025 |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,648.97 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Dugan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.